Search results
Showing 46 to 60 of 101 results for methotrexate
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Secukinumab for treating active ankylosing spondylitis (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.